---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-005768"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:17:21.929177+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences Q1 net loss $1.0M; pivots to metabolic disease diagnostics, plans FDA de novo trial

## Summary
- Net loss $1.0M in Q1 2025 vs $2.8M in Q1 2024; operating expenses down 46% to $1.5M.
- Cash burn improved to $1.2M in Q1 2025 from $1.7M in Q1 2024; cash at April 30 was $2.5M after $0.8M ATM raise.
- Strategic pivot to point-of-care liver fat diagnostics for metabolic disease; redesigned TAEUS system with AI.
- Revised FDA regulatory strategy: plans prospective multicenter trial of ~250 subjects for De Novo submission.
- Two new patents issued in China, bringing IP portfolio to 84 total.

## SEC filing metadata
- accession: 0001654954-25-005768
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495425005768/0001654954-25-005768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495425005768/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-005768
- JSON: https://secwatch.observer/filing/0001654954-25-005768.json
- Plain text: https://secwatch.observer/filing/0001654954-25-005768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.